SHATTUCK LABS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • July 29th, 2022 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
Shattuck Labs, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 5th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is entered into as of __________ by and between Shattuck Labs, Inc., a Delaware corporation (the “Company”), and __________ (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company.
EMPLOYMENT AGREEMENTEmployment Agreement • February 29th, 2024 • Shattuck Labs, Inc. • Pharmaceutical preparations • Texas
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of June 1, 2021 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Abhinav Shukla (“Executive”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 22nd, 2023 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 21, 2023, by and among SHATTUCK LABS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 16th, 2021 • Shattuck Labs, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 (this “Amendment”) is entered into as of this 12th day of March, 2021 by and between Shattuck Labs, Inc. (the “Company”) and Erin Ator Thomson (“Executive”) and amends that certain Employment Agreement dated as of December 5, 2019 (the “Agreement”) between the Company and Executive.
Shattuck Labs, Inc. [•] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 22nd, 2023 • Shattuck Labs, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is dated as of December 21, 2023, by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
EXCLUSIVE LICENSE AGREEMENT By and between Shattuck Labs, Inc. and Heat Biologics, Inc. Effective as of June 3, 2016Exclusive License Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (this “Agreement”), effective this 3rd day of June, 2016 (the “Effective Date”), is between Shattuck Labs, Inc., a Delaware corporation (“Shattuck”), and Heat Biologics, Inc., a Delaware corporation (“Heat”). Shattuck and Heat are each a “Party” and collectively the “Parties.”
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 (the “Amendment”) is entered into as of this 27th day of March, 2020 by and between Shattuck Labs, Inc. (the “Company”) and Taylor Schreiber (the “Executive”) and amends that certain Employment Agreement dated as of December 5, 2019 (the “Agreement”) between the Company and the Executive.
SHATTUCK LABS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of June 12, 2020 by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder,” and any other Person that becomes a party to this Agreement in accordance with Section 7.14 hereof.
Office Lease Austin, Texas Between Shattuck Labs, Inc. (Tenant) and International Bank of Commerce, Laredo, Texas (Landlord) Suite 1200, IBC Bank Plaza With an Effective Date of January 8th 2021Office Lease • March 16th, 2021 • Shattuck Labs, Inc. • Pharmaceutical preparations
Page KEY TERMS SCHEDULE 1. PROJECT 1 2. LEASED PREMISES 1 3. COMMENCEMENT DATE 1 4. EARLY ACCESS 1 5. INITIAL TERM 2 6. BASE RENTAL RATE 2 7. OPERATING EXPENSES 2 8. TENANT IMPROVEMENT ALLOWANCE 2 9. CONSTRUCTION PROCESS/TENANT CONSTRUCTION 3 10. ASSIGNMENT AND SUBLETTING 3 11. COMPLIANCE WITH LAW 3 12. BUILDING MANAGEMENT 3 13. NON-DISTURBANCE AGREEMENT 3 14. PARKING 3 15. BUILDING HOURS 3 16. AFTER HOURS HVAC CHARGES 3 17. SIGNAGE AND DIRECTORY 3 18. SECURITY DEPOSIT 4 19. BROKERS 4 ADDITIONAL TERMS AND CONDITIONS 5 1. LEASE AGREEMENT 5 2. RENT 5 A. Types of Rent 5 B. Place and Method of Payment 5 C. Payment of Rent 5 D. Payment of Operating Cost Share Rent 5 E. Computation of Base Rent and Rent Adjustments 9 3. PREPARATION, CONDITION, POSSESSION AND SURRENDER OF LEASED PREMISES 10 A. Condition of Premises 10 B. Tenant's Possession 10 C. Maintenance 10 4. PROJECT SERVICES 11 A. Heating and Air Conditioning 11 B. Elevators 11 C. Electricity 11 D. Water 11 E. Janitorial Service 11 G. I
TERMINATION AGREEMENTTermination Agreement • November 9th, 2021 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This Termination Agreement (this “Agreement”), dated as of November 8, 2021 (the “Effective Date”), is entered into by and between Millennium Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Millennium”), and Shattuck Labs, Inc., a Delaware corporation having its principal place of business at 500 W. 5th St., Suite 1200, Austin, TX 78701 (“Shattuck”). This Agreement refers to Shattuck or Millennium singularly as a “Party” or collectively as the “Parties”, and capitalized terms used herein without definition shall have the meaning set forth in the Collaboration Agreement (as defined below).
SHATTUCK LABS, INC. and MILLENNIUM PHARMACEUTICALS, INC. COLLABORATION AGREEMENT Effective as of August 8, 2017Collaboration Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This Collaboration Agreement (this “Agreement”), effective this 8th day of August, 2017 (the “Effective Date”), is between Millennium Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Millennium”), and Shattuck Labs, Inc., a Delaware corporation having its principal place of business at 3317 Bowman Avenue, Austin, TX 78703 (“Shattuck”). Millennium and Shattuck are each sometimes referred to herein as a “Party” and collectively as the “Parties.”
LEASE AGREEMENT BETWEEN PARMER RTP, LLC, AS LANDLORD, AND SHATTUCK LABS, INC., AS TENANT DATED APRIL 17, 2018 DURHAM, NORTH CAROLINALease Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • Texas
This Lease Agreement (this “Lease”) is entered into as of April ____, 2018, between PARMER RTP, LLC, a Delaware limited liability company (“Landlord”), and SHATTUCK LABS, INC., a Delaware corporation (“Tenant”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • February 23rd, 2023 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
as of February 4, 2022 (the “Effective Date”), is by and between Shattuck Labs, Inc., a Delaware corporation (“Shattuck”), with a place of business at 500 W. 5th Street, Suite 1200, Austin, Texas 78701 (“Shattuck”) and ImmunoGen, Inc., having a place of business at 830 Winter Street, Waltham, MA 02451-1477, USA (“ImmunoGen”). Shattuck and ImmunoGen are each referred to herein individually as “Party” and collectively “Parties”.
Shattuck Labs, Inc. 4,651,163 Shares of Common Stock ($0.0001 par value) Underwriting AgreementShattuck Labs, Inc. • December 22nd, 2023 • Pharmaceutical preparations • New York
Shattuck Labs, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, 4,651,163 shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I hereto other than you, the term Representative as used herein shall mean you, as Underwriters, and the term Underwriters shall mean either the singular or plural as the context requires.
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 (the “Amendment”) is entered into as of this 27th day of March, 2020 by and between Shattuck Labs, Inc. (the “Company”) and Josiah C. Hornblower (the “Executive”) and amends that certain Employment Agreement dated as of December 5, 2019 (the “Agreement”) between the Company and the Executive.
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 16th, 2021 • Shattuck Labs, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 (this “Amendment”) is entered into as of this 12th day of March, 2021 by and between Shattuck Labs, Inc. (the “Company”) and Andrew Neill (“Executive”) and amends that certain Employment Agreement dated as of December 5, 2019, between the Company and Executive.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Master Services AgreementMaster Services Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This Master Services Agreement (this “Agreement”) dated March 31, 2017 (the “Effective Date”), between Shattuck Labs, Inc., having a place of business at 3317 Bowman Ave, Austin, TX 78703 (“Client”) and KBI Biopharma, Inc., having a place of business at 1101 Hamlin Road, Durham, North Carolina 27704 (“KBI Biopharma”) (Client and KBI Biopharma, each a “Party”, and collectively, the “Parties”).
